Humpath.com - Human pathology

Home > A. Molecular pathology > KRT19

KRT19

HGNC:6436 MIM.148020

Friday 14 December 2007

Prognosis marker

- In a multivariate analysis, the CK19 status is shown to be independent of the WHO criteria. CK19 staining is a potential additional prognostic marker independent from the WHO criteria for pancreatic endocrine tumors. (18059224)

Cytokeratin 19 (CK19) messenger RNA amplification

Sentinel node of breast cancer pathologic analysis shows great limitations related to reproducibility and challenges pathologists with respect to methodology and standardization. (21326035)

Recently, a new, highly specific and sensitive molecular procedure has been developed, based on cytokeratin 19 messenger RNA amplification, which allows for fast and effective intraoperative evaluation of the SN.

Exhaustive histopathologic procedure and this molecular method similarly distinguish between benign and malignant lymph nodes but the type of metastasis is better defined and stratified by the molecular method.

This molecular method should be recommended for SN diagnosis because besides its high sensitivity, specificity, and operating room adequacy, it may allow for standardization for SN evaluation. (21326035)

References

- Molecular diagnosis of sentinel lymph nodes for breast cancer: one step ahead for standardization. Laia BV, Marcos MB, Refael CM, Francisco SC, Jose T, Blai BS, Maria de LC. Diagn Mol Pathol. 2011 Mar;20(1):18-21. PMID: 21326035

- WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P, Perren A. Am J Surg Pathol. 2007 Nov;31(11):1677-82. PMID: 18059224

- Nasser SM, Pitman MB, Pilch BZ, Faquin WC. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining. Cancer. 2000 Oct 25;90(5):307-11. PMID: 11038428